Mahendra G. Shah Ph.D.
Mahendra G. Shah, Ph.D. is a highly successful pharmaceutical entrepreneur and executive who has been at Vivo Capital since March 2010. He is also the founder and executive chairman of Semnur Pharmaceuticals. Dr. Shah currently serves as chairman of the board of Essentialis Therapeutics, board member of Biotie Therapies (NASDAQ: BITI), and a member of… read more »
Brent Ahrens, M.S., M.B.A.
General Partner, Canaan Partners
Brent Ahrens joined Canaan in 1999 as a member of the Kauffman Fellows Program. A raconteur extraordinaire, in his work hours, Brent focuses on healthcare investments and has led investments in life sciences companies such as DexCom (DXCM), Revivant (acquired by ZOLL), Peninsula Pharmaceuticals (acquired by JNJ), Cerexa (acquired by FRX), Calixa (acquired by CBST),… read more »
Edgar G. Engleman, M.D.
Managing Partner, Vivo Capital
Edgar Engleman is a founding member of Vivo Capital, LLC (formerly BioAsia Investments). Dr. Engleman is Professor of Pathology and Medicine at Stanford University School of Medicine, where he oversees the Stanford Blood Center and his own immunology research group. An editor of numerous scientific journals and the inventor of multiple patented technologies, Dr. Engleman… read more »
Daniel Estes, Ph.D.
Partner, Frazier Healthcare
Daniel Estes joined Frazier Healthcare in 2011 and is a Principal on the Frazier Life Sciences team, focusing on investments in biopharmaceutical and specialty pharmaceutical companies. Dan is a member of the board of directors at Semnur Pharmaceuticals, and is a board observer at Atterocor. He has also been involved in Frazier’s investments in Acerta,… read more »
Scott Whitcup MD
Former Executive VP, R&D and Chief Scientific Officer, Allergan, Inc.
Scott Whitcup has been Executive Vice President, Research and Development since July 2004 and in April 2009 became Chief Scientific Officer. Dr. Whitcup joined Allergan in 2000. Prior to joining Allergan, Dr. Whitcup served as the Clinical Director of the National Eye Institute at the National Institutes of Health. As Clinical Director, Dr. Whitcup’s leadership… read more »
Chief Executive Officer, Semnur Pharmaceuticals, Inc.
Jaisim Shah is a successful life science leader with significant success in global business development and product commercialization. Jaisim’s track record of success in leading teams in the commercialization of some of today’s most recognized pharmaceutical brands. Innovation, collaboration and patient care has been at the heart and soul of his extensive life science career and they… read more »
Dmitri Lissin, M.D.
Chief Medical Officer and Senior Vice President, Clinical Development and Medical Affairs
Dmitri Lissin currently serves as Chief Medical Officer and Senior Vice President, Clinical Development and Medical Affairs of Semnur Pharmaceuticals. Prior to Semnur, from 2011-2015, Dmitri was Vice President of Clinical Development at Xenoport, responsible for conduct of multiple clinical research programs in neurology and dermatology. From 2006-2011 Dmitri directed a clinical research team and served… read more »
Suketu D. Desai, Ph.D.
Chief Technical Officer and Senior Vice President, Chemistry, Manufacturing and Controls
Suketu D. Desai, Ph.D., currently serves as Chief Technical Officer and Senior Vice President, Chemistry, Manufacturing and Controls (CMC) at Semnur Pharmaceuticals, Inc. Prior to Semnur during 2014-2015, Suketu was Vice President of Biologics Development and Manufacturing responsible for biologics drug substance and drug product, technical due diligence and commercial technical operations at Allergan, Inc…. read more »